Loading…
Biomarkers in Colorectal Cancer: Current Research and Future Prospects
Colorectal cancer (CRC) is a leading cause of death worldwide, despite progress made in detection and management through surgery, chemotherapy, radiotherapy, and immunotherapy. Novel therapeutic agents have improved survival in both the adjuvant and advanced disease settings, albeit with an increase...
Saved in:
| Published in: | International journal of molecular sciences 2020-07, Vol.21 (15), p.5311 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c478t-38322067aa1d990fbd05ef77575dce97e18f591536898af107eb0ea09fbeaf753 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c478t-38322067aa1d990fbd05ef77575dce97e18f591536898af107eb0ea09fbeaf753 |
| container_end_page | |
| container_issue | 15 |
| container_start_page | 5311 |
| container_title | International journal of molecular sciences |
| container_volume | 21 |
| creator | Ogunwobi, Olorunseun O Mahmood, Fahad Akingboye, Akinfemi |
| description | Colorectal cancer (CRC) is a leading cause of death worldwide, despite progress made in detection and management through surgery, chemotherapy, radiotherapy, and immunotherapy. Novel therapeutic agents have improved survival in both the adjuvant and advanced disease settings, albeit with an increased risk of toxicity and cost. However, metastatic disease continues to have a poor long-term prognosis and significant challenges remain due to late stage diagnosis and treatment failure. Biomarkers are a key tool in early detection, prognostication, survival, and predicting treatment response. The past three decades have seen advances in genomics and molecular pathology of cancer biomarkers, allowing for greater individualization of therapy with a positive impact on survival outcomes. Clinically useful predictive biomarkers aid clinical decision making, such as the presence of
gene mutations predicting benefit from epidermal growth factor receptor (EGFR) inhibiting antibodies. However, few biomarkers have been translated into clinical practice highlighting the need for further investigation. We review a range of protein, DNA and RNA-based biomarkers under investigation for diagnostic, predictive, and prognostic properties for CRC. In particular, long non-coding RNAs (lncRNA), have been investigated as biomarkers in a range of cancers including colorectal cancer. Specifically, we evaluate the potential role of lncRNA plasmacytoma variant translocation 1 (
), an oncogene, as a diagnostic, prognostic, and therapeutic biomarker in colorectal cancer. |
| doi_str_mv | 10.3390/ijms21155311 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e566a643479f4297b0d59bb95a23979b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_e566a643479f4297b0d59bb95a23979b</doaj_id><sourcerecordid>2429477066</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-38322067aa1d990fbd05ef77575dce97e18f591536898af107eb0ea09fbeaf753</originalsourceid><addsrcrecordid>eNpdkUtLxDAURoMovneupeDGhaN5NE3jQtDiqCAooutw295ox04zJq3gvzfjqIyuEpLDuY-PkD1Gj4XQ9KSZTANnTErB2ArZZCnnI0oztbp03yBbIUwo5YJLvU42BFc801xskvFF46bgX9GHpOmSwrXOY9VDmxTQVehPk2LwHrs-ecCA4KuXBLo6GQ_94DG59y7MIh52yJqFNuDu97lNnsaXj8X16Pbu6qY4vx1Vqcr7kcgF57EfAFZrTW1ZU4lWKalkXaFWyHIrNZMiy3UOllGFJUWg2pYIVkmxTW4W3trBxMx8E3v_MA4a8_Xg_LMB3zdViwZllkGWilRpm3KtSlpLXZZaAhda6TK6zhau2VBOMdbveg_tH-nfn655Mc_u3ahU8FRkUXD4LfDubcDQm2kTKmxb6NANwfBYlsZcch3Rg3_oxA2-i6v6olKlaDYXHi2oKu41eLS_zTBq5mGb5bAjvr88wC_8k674BLacpFE</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2429477066</pqid></control><display><type>article</type><title>Biomarkers in Colorectal Cancer: Current Research and Future Prospects</title><source>Open Access: PubMed Central</source><source>Publicly Available Content (ProQuest)</source><creator>Ogunwobi, Olorunseun O ; Mahmood, Fahad ; Akingboye, Akinfemi</creator><creatorcontrib>Ogunwobi, Olorunseun O ; Mahmood, Fahad ; Akingboye, Akinfemi</creatorcontrib><description>Colorectal cancer (CRC) is a leading cause of death worldwide, despite progress made in detection and management through surgery, chemotherapy, radiotherapy, and immunotherapy. Novel therapeutic agents have improved survival in both the adjuvant and advanced disease settings, albeit with an increased risk of toxicity and cost. However, metastatic disease continues to have a poor long-term prognosis and significant challenges remain due to late stage diagnosis and treatment failure. Biomarkers are a key tool in early detection, prognostication, survival, and predicting treatment response. The past three decades have seen advances in genomics and molecular pathology of cancer biomarkers, allowing for greater individualization of therapy with a positive impact on survival outcomes. Clinically useful predictive biomarkers aid clinical decision making, such as the presence of
gene mutations predicting benefit from epidermal growth factor receptor (EGFR) inhibiting antibodies. However, few biomarkers have been translated into clinical practice highlighting the need for further investigation. We review a range of protein, DNA and RNA-based biomarkers under investigation for diagnostic, predictive, and prognostic properties for CRC. In particular, long non-coding RNAs (lncRNA), have been investigated as biomarkers in a range of cancers including colorectal cancer. Specifically, we evaluate the potential role of lncRNA plasmacytoma variant translocation 1 (
), an oncogene, as a diagnostic, prognostic, and therapeutic biomarker in colorectal cancer.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms21155311</identifier><identifier>PMID: 32726923</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>biomarker ; Biomarkers ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Cancer ; Chemical compounds ; Chemotherapy ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - diagnosis ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - metabolism ; Colorectal Neoplasms - pathology ; Decision making ; Deoxyribonucleic acid ; diagnosis ; Diagnostic systems ; DNA ; Epidermal growth factor ; Epidermal growth factor receptors ; ErbB Receptors - genetics ; ErbB Receptors - metabolism ; Growth factors ; Health services ; Humans ; Immunotherapy ; Kinases ; Metastases ; Mortality ; Mutation ; Non-coding RNA ; Pharmacology ; Plasmacytoma ; Prognosis ; prognostication ; Proto-Oncogene Proteins p21(ras) - genetics ; Proto-Oncogene Proteins p21(ras) - metabolism ; PVT1 ; Radiation therapy ; Review ; RNA, Long Noncoding - genetics ; RNA, Long Noncoding - metabolism ; RNA, Neoplasm - genetics ; RNA, Neoplasm - metabolism ; screening ; Survival ; Toxicity</subject><ispartof>International journal of molecular sciences, 2020-07, Vol.21 (15), p.5311</ispartof><rights>2020. This work is licensed under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 by the authors. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-38322067aa1d990fbd05ef77575dce97e18f591536898af107eb0ea09fbeaf753</citedby><cites>FETCH-LOGICAL-c478t-38322067aa1d990fbd05ef77575dce97e18f591536898af107eb0ea09fbeaf753</cites><orcidid>0000-0003-3388-2137 ; 0000-0003-1776-8828</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2429477066/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2429477066?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32726923$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ogunwobi, Olorunseun O</creatorcontrib><creatorcontrib>Mahmood, Fahad</creatorcontrib><creatorcontrib>Akingboye, Akinfemi</creatorcontrib><title>Biomarkers in Colorectal Cancer: Current Research and Future Prospects</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Colorectal cancer (CRC) is a leading cause of death worldwide, despite progress made in detection and management through surgery, chemotherapy, radiotherapy, and immunotherapy. Novel therapeutic agents have improved survival in both the adjuvant and advanced disease settings, albeit with an increased risk of toxicity and cost. However, metastatic disease continues to have a poor long-term prognosis and significant challenges remain due to late stage diagnosis and treatment failure. Biomarkers are a key tool in early detection, prognostication, survival, and predicting treatment response. The past three decades have seen advances in genomics and molecular pathology of cancer biomarkers, allowing for greater individualization of therapy with a positive impact on survival outcomes. Clinically useful predictive biomarkers aid clinical decision making, such as the presence of
gene mutations predicting benefit from epidermal growth factor receptor (EGFR) inhibiting antibodies. However, few biomarkers have been translated into clinical practice highlighting the need for further investigation. We review a range of protein, DNA and RNA-based biomarkers under investigation for diagnostic, predictive, and prognostic properties for CRC. In particular, long non-coding RNAs (lncRNA), have been investigated as biomarkers in a range of cancers including colorectal cancer. Specifically, we evaluate the potential role of lncRNA plasmacytoma variant translocation 1 (
), an oncogene, as a diagnostic, prognostic, and therapeutic biomarker in colorectal cancer.</description><subject>biomarker</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Cancer</subject><subject>Chemical compounds</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - diagnosis</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - metabolism</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Decision making</subject><subject>Deoxyribonucleic acid</subject><subject>diagnosis</subject><subject>Diagnostic systems</subject><subject>DNA</subject><subject>Epidermal growth factor</subject><subject>Epidermal growth factor receptors</subject><subject>ErbB Receptors - genetics</subject><subject>ErbB Receptors - metabolism</subject><subject>Growth factors</subject><subject>Health services</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Kinases</subject><subject>Metastases</subject><subject>Mortality</subject><subject>Mutation</subject><subject>Non-coding RNA</subject><subject>Pharmacology</subject><subject>Plasmacytoma</subject><subject>Prognosis</subject><subject>prognostication</subject><subject>Proto-Oncogene Proteins p21(ras) - genetics</subject><subject>Proto-Oncogene Proteins p21(ras) - metabolism</subject><subject>PVT1</subject><subject>Radiation therapy</subject><subject>Review</subject><subject>RNA, Long Noncoding - genetics</subject><subject>RNA, Long Noncoding - metabolism</subject><subject>RNA, Neoplasm - genetics</subject><subject>RNA, Neoplasm - metabolism</subject><subject>screening</subject><subject>Survival</subject><subject>Toxicity</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkUtLxDAURoMovneupeDGhaN5NE3jQtDiqCAooutw295ox04zJq3gvzfjqIyuEpLDuY-PkD1Gj4XQ9KSZTANnTErB2ArZZCnnI0oztbp03yBbIUwo5YJLvU42BFc801xskvFF46bgX9GHpOmSwrXOY9VDmxTQVehPk2LwHrs-ecCA4KuXBLo6GQ_94DG59y7MIh52yJqFNuDu97lNnsaXj8X16Pbu6qY4vx1Vqcr7kcgF57EfAFZrTW1ZU4lWKalkXaFWyHIrNZMiy3UOllGFJUWg2pYIVkmxTW4W3trBxMx8E3v_MA4a8_Xg_LMB3zdViwZllkGWilRpm3KtSlpLXZZaAhda6TK6zhau2VBOMdbveg_tH-nfn655Mc_u3ahU8FRkUXD4LfDubcDQm2kTKmxb6NANwfBYlsZcch3Rg3_oxA2-i6v6olKlaDYXHi2oKu41eLS_zTBq5mGb5bAjvr88wC_8k674BLacpFE</recordid><startdate>20200727</startdate><enddate>20200727</enddate><creator>Ogunwobi, Olorunseun O</creator><creator>Mahmood, Fahad</creator><creator>Akingboye, Akinfemi</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3388-2137</orcidid><orcidid>https://orcid.org/0000-0003-1776-8828</orcidid></search><sort><creationdate>20200727</creationdate><title>Biomarkers in Colorectal Cancer: Current Research and Future Prospects</title><author>Ogunwobi, Olorunseun O ; Mahmood, Fahad ; Akingboye, Akinfemi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-38322067aa1d990fbd05ef77575dce97e18f591536898af107eb0ea09fbeaf753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>biomarker</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Cancer</topic><topic>Chemical compounds</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - diagnosis</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - metabolism</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Decision making</topic><topic>Deoxyribonucleic acid</topic><topic>diagnosis</topic><topic>Diagnostic systems</topic><topic>DNA</topic><topic>Epidermal growth factor</topic><topic>Epidermal growth factor receptors</topic><topic>ErbB Receptors - genetics</topic><topic>ErbB Receptors - metabolism</topic><topic>Growth factors</topic><topic>Health services</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Kinases</topic><topic>Metastases</topic><topic>Mortality</topic><topic>Mutation</topic><topic>Non-coding RNA</topic><topic>Pharmacology</topic><topic>Plasmacytoma</topic><topic>Prognosis</topic><topic>prognostication</topic><topic>Proto-Oncogene Proteins p21(ras) - genetics</topic><topic>Proto-Oncogene Proteins p21(ras) - metabolism</topic><topic>PVT1</topic><topic>Radiation therapy</topic><topic>Review</topic><topic>RNA, Long Noncoding - genetics</topic><topic>RNA, Long Noncoding - metabolism</topic><topic>RNA, Neoplasm - genetics</topic><topic>RNA, Neoplasm - metabolism</topic><topic>screening</topic><topic>Survival</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ogunwobi, Olorunseun O</creatorcontrib><creatorcontrib>Mahmood, Fahad</creatorcontrib><creatorcontrib>Akingboye, Akinfemi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ogunwobi, Olorunseun O</au><au>Mahmood, Fahad</au><au>Akingboye, Akinfemi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biomarkers in Colorectal Cancer: Current Research and Future Prospects</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2020-07-27</date><risdate>2020</risdate><volume>21</volume><issue>15</issue><spage>5311</spage><pages>5311-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Colorectal cancer (CRC) is a leading cause of death worldwide, despite progress made in detection and management through surgery, chemotherapy, radiotherapy, and immunotherapy. Novel therapeutic agents have improved survival in both the adjuvant and advanced disease settings, albeit with an increased risk of toxicity and cost. However, metastatic disease continues to have a poor long-term prognosis and significant challenges remain due to late stage diagnosis and treatment failure. Biomarkers are a key tool in early detection, prognostication, survival, and predicting treatment response. The past three decades have seen advances in genomics and molecular pathology of cancer biomarkers, allowing for greater individualization of therapy with a positive impact on survival outcomes. Clinically useful predictive biomarkers aid clinical decision making, such as the presence of
gene mutations predicting benefit from epidermal growth factor receptor (EGFR) inhibiting antibodies. However, few biomarkers have been translated into clinical practice highlighting the need for further investigation. We review a range of protein, DNA and RNA-based biomarkers under investigation for diagnostic, predictive, and prognostic properties for CRC. In particular, long non-coding RNAs (lncRNA), have been investigated as biomarkers in a range of cancers including colorectal cancer. Specifically, we evaluate the potential role of lncRNA plasmacytoma variant translocation 1 (
), an oncogene, as a diagnostic, prognostic, and therapeutic biomarker in colorectal cancer.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>32726923</pmid><doi>10.3390/ijms21155311</doi><orcidid>https://orcid.org/0000-0003-3388-2137</orcidid><orcidid>https://orcid.org/0000-0003-1776-8828</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2020-07, Vol.21 (15), p.5311 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_e566a643479f4297b0d59bb95a23979b |
| source | Open Access: PubMed Central; Publicly Available Content (ProQuest) |
| subjects | biomarker Biomarkers Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Cancer Chemical compounds Chemotherapy Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - diagnosis Colorectal Neoplasms - genetics Colorectal Neoplasms - metabolism Colorectal Neoplasms - pathology Decision making Deoxyribonucleic acid diagnosis Diagnostic systems DNA Epidermal growth factor Epidermal growth factor receptors ErbB Receptors - genetics ErbB Receptors - metabolism Growth factors Health services Humans Immunotherapy Kinases Metastases Mortality Mutation Non-coding RNA Pharmacology Plasmacytoma Prognosis prognostication Proto-Oncogene Proteins p21(ras) - genetics Proto-Oncogene Proteins p21(ras) - metabolism PVT1 Radiation therapy Review RNA, Long Noncoding - genetics RNA, Long Noncoding - metabolism RNA, Neoplasm - genetics RNA, Neoplasm - metabolism screening Survival Toxicity |
| title | Biomarkers in Colorectal Cancer: Current Research and Future Prospects |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T02%3A41%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biomarkers%20in%20Colorectal%20Cancer:%20Current%20Research%20and%20Future%20Prospects&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Ogunwobi,%20Olorunseun%20O&rft.date=2020-07-27&rft.volume=21&rft.issue=15&rft.spage=5311&rft.pages=5311-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms21155311&rft_dat=%3Cproquest_doaj_%3E2429477066%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c478t-38322067aa1d990fbd05ef77575dce97e18f591536898af107eb0ea09fbeaf753%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2429477066&rft_id=info:pmid/32726923&rfr_iscdi=true |